Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 2
- RSC Med Chem. 2020 Sep 18;11(12):1379-1385. doi: 10.1039/d0md00175a.
- 1. Redx Anti-Infectives Ltd Alderley Park Macclesfield SK10 4TG Cheshire UK.
Building on our previously-reported novel tricyclic Topoisomerase inhibitors (NTTIs), we disclose the discovery of REDX07965, which has an MIC90 of 0.5 μg mL-1 against Staphylococcus aureus, favourable in vitro pharmacokinetic properties, selectivity versus human Topoisomerase II and an acceptable toxicity profile. The results herein validate a rational design approach to address the urgent unmet medical need for novel Antibiotics.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Infection